Kontafarma China Holdings Ltd
01312
Company Profile
Business description
Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs active pharmaceutical ingredients and API intermediates in the PRC, operating of fitness centres and provision of consultation services for fitness and health activities and operating of the franchise business for royalty fee income. The operating segments include the pharmaceutical business and the Fitness business. The majority of its revenue derives from the pharmaceutical business segment.
Contact
30 Harbour Road
Room 12A 09-20, 12th Floor, Sun Hung Kai Centre
Wanchai
Hong Kong
HKGT: +852 27316500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
688
Stocks News & Analysis
stocks
Telstra earnings: No need to get hysterical over mobile
Earnings report in-line with expectations.
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,233.50 | 21.40 | 0.23% |
| CAC 40 | 7,884.05 | 39.40 | -0.50% |
| DAX 40 | 24,314.77 | 44.53 | -0.18% |
| Dow JONES (US) | 44,887.08 | 59.04 | -0.13% |
| FTSE 100 | 9,157.74 | 18.84 | 0.21% |
| HKSE | 25,176.85 | 93.22 | -0.37% |
| NASDAQ | 21,599.06 | 23.91 | -0.11% |
| Nikkei 225 | 43,714.31 | 336.00 | 0.77% |
| NZX 50 Index | 12,970.64 | 81.26 | 0.63% |
| S&P 500 | 6,442.89 | 6.91 | -0.11% |
| S&P/ASX 200 | 8,959.30 | 20.70 | 0.23% |
| SSE Composite Index | 3,728.03 | 31.26 | 0.85% |